Journal of Bioremediation & Biodegradation

Singh
J Bioremediat Biodegrad
2021,12:3

Market Analysis Open Access

Market Analysis on Bioavailability & Bioequivalence

Mewa Singh *

Professor,USA ,Email: mewasinghsandhu@hotmail.com

Its an enormous pleasure and feel respected to organize 12th World Congress on Bioavailability & Bioequivalence scheduled during April 08-09, 2020 at Paris, France. The conference is mainly focussed on the theme of "Expanding new horizons in advances of Bioavailability"

BABE 2020 is designed with the keynote sessions, session lectures, and poster presentations, presentations from the young researchers, panel Discussions, and the B2B meetings with world-renowned speakers from the stream of clinical and pharmaceutical sciences. It provides the best platform for the researchers to the researchers all over globe to introduce themselves to the innovative world with their unique research. Its an open forum to discuss new researches and the challenges faced during the BA/BE studies, manufacturing the generic drugs and their effect on the public health.

Low bioavailability is one of the primary concerns associated with marketed drugs; in fact, various studies indicate that around 40% of available drugs are poorly bioavailable / soluble. As the drug developers shift their focus towards development of lipophilic drug compounds, the issue with aqueous solubility / bioavailability of the drugs is likely to increase further. It is estimated that around 90% of NCEs belong to BCS class II and IV, which are known to be associated with low solubility / permeability. Given that a large number of drugs fail to reach the market due to poor bioavailability, the industry is looking for various tools / methods to mitigate this challenge. Moreover, as many companies seek to re-formulate existing product candidates that exhibit poor bioavailability the demand for novel bioavailability enhancement methods has grown significantly.

To cater to this increasing demand, several contract manufacturers and technology providers have emerged in this domain. With more than 150 companies offering technologies / services for bioavailability enhancement, the market is highly fragmented; having said that, several mergers / acquisitions have also taken place as stakeholders strive to broaden their respective service portfolios. A number of players have developed novel, state-of-the art technologies to maintain a competitive edge in this rapidly emerging market. As drug developers continue to evaluate novel drug targets and classes, the bioavailability enhancement domain is expected to grow at a steady pace. In fact, since 2010, more than 4,000 articles, evaluating various bioavailability enhancement technologies have been published across several reputed journals. In addition, more than 6,000 patents have been filed post 2010, providing a significant scientific push to the development of novel approaches.